bioAffinity Technologies reported CyPath Lung test volume surged 216% year‑over‑year in Q2 2026, pushing quarterly revenue up 19% to $1.5 million. The rapid adoption signals strong market demand and narrows the company’s loss, offering investors a clearer path to profitability as commercialization accelerates.
Key Highlights
- CyPath Lung test volume climbed 216% YoY in Q2 2026, delivering 1,097 reports in the first half of the year.
- Revenue rose 19% to $1.5 million, while net loss narrowed to $3.4 million, reflecting higher sales and cost efficiencies.
- Clinical development expenses jumped to $476,000 as a longitudinal trial began enrollment at 11 VA and military sites.
- The company completed a $3.2 million public offering to fund commercialization and pipeline expansion.
BioAffinity Technologies announced a 216% year‑over‑year surge in CyPath Lung test volume for the second quarter of 2026, delivering 1,097 reports in the first six months and propelling quarterly revenue to $1.5 million, a 19% rise from the prior year. The expansion of physician adoption and a 122% jump in ordering clinics underscore the test’s growing clinical relevance, while existing customers increased their orders by 71% YoY. This rapid uptake not only validates the technology but also positions the company for stronger cash flows as it scales operations.
The momentum suggests that the firm’s commercial strategy is resonating with providers, setting the stage for continued top‑line growth.
216% Test Volume Surge
CyPath Lung’s dramatic volume increase reflects a broadening footprint across more than twice as many physician offices and clinics compared with Q2 2025. The test, which uses flow cytometry and AI to detect malignancy markers in sputum, saw an unprecedented rise in orders, with clinics ordering the assay up 122% and existing clients boosting repeat orders by 71% during the first half of 2026. The company’s distribution network, anchored by Precision Pathology Laboratory Services, enabled rapid scaling, while educational initiatives such as webinars and podcasts amplified physician awareness.
This surge translates into higher per‑test revenue and a deeper market penetration that could lock in long‑term demand. The implication is that sustained volume growth will improve unit economics and reduce the cost per acquisition for new users.
Revenue and Cost Profile
Quarterly revenue of $1.5 million represented a 19% increase over the $1.3 million earned in the same period last year, driven primarily by the expanded CyPath Lung sales. Operating expenses climbed to $4.8 million from $3.8 million, reflecting higher direct costs of $1.1 million versus $1.0 million, elevated R&D spending of $362,000 (up 16% YoY), and a jump in clinical development outlays to $476,000 as the longitudinal study launched. SG&A rose to $2.9 million from $2.2 million, largely due to additional sales and administrative staff.
Net loss narrowed to $3.4 million from $4.1 million, while cash and equivalents fell to $2.4 million from $6.4 million at year‑end 2025. The tighter loss margin indicates that revenue growth is beginning to offset rising expenses, yet the company remains cash‑intensive as it funds trial enrollment and market expansion.
Clinical and Pipeline Momentum
The longitudinal clinical trial evaluating CyPath Lung’s performance commenced enrollment at 11 sites, including nine VA and military medical centers, with funding from the John P. Murtha Cancer Center Research Program. Early data from the test’s key validation study showed 92% sensitivity, 87% specificity, 88% accuracy, and a 99% negative predictive value, reinforcing its diagnostic credibility. Parallel efforts are expanding into precision diagnostics for asthma and COPD, leveraging platform’s ability to identify antibody drug receptors in sputum, and advancing siRNA‑based topical therapies for squamous and basal cell skin cancers.
A collaboration with Pictor® further broadens the company’s proteomic capabilities. These initiatives diversify the pipeline and create cross‑selling opportunities, potentially accelerating revenue beyond the lung cancer segment.
Funding and Forward Outlook
The infusion bolsters the company’s liquidity, though cash on hand declined to $2.4 million as the firm invests heavily in trial operations and sales expansion. With the longitudinal study now enrolling patients, upcoming interim analyses will be critical in demonstrating real‑world effectiveness and could unlock further reimbursement pathways. Investors should monitor the company’s next quarterly earnings release, where management is expected to update on trial enrollment progress and the impact of recent collaborations on the pipeline.
Analysis based on the Form 8-K filed 7 August 2026; figures verified against the filing.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...